# Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

> **NCT02680951** · PHASE1 · WITHDRAWN · sponsor: **Emory University**

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** Idarubicin
- **DRUG:** Intrathecal (IT) cytarabine

## Key facts

- **NCT ID:** NCT02680951
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2017-12-15
- **Final completion:** 2017-12-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn due to lack of participants.
- **Last updated:** 2018-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02680951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02680951, "Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02680951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*